The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia

Clinical Chemistry

Volumn 44, Issue 10, 1998, Pages 2115-2119

  Saedi, Mohammad S ^a   Hill, Timothy M ^a   Kuus Reichel, Kristine ^a   Kumar, Abhay ^a   Payne, Janice ^a   Mikolajczyk, Stephen D ^a   Wolfert, Robert L ^a   Rittenhouse, Harry G ^a  

^a Hybritech Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; KALLIKREIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOBLOTTING; MAMMAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

MAMMALIA;

EID: 0031671272     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.10.2115     Document Type: Article

References (21)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324: 1156-61.
3. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez J-L, Emond J. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992;147:846-52.
4. Oesterling JE, Chan DW, Epstein JL, Kimbal AW Jr, Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766-72.
5. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995;45: 729-44.
6. Rittenhouse H, Tindall D, Klee G, Bostwick D, Saedi M, Grauer L, et al. Characterization and evaluation of hK2: a potential prostate cancer marker, closely related to PSA. In: Murphy G, Denis L, Chatelain C, Griffiths K, Khoury S, eds. First international consultation on prostate cancer. Scientific Communication International Ltd, 1997:133-40.
7. Kumar A, Goel AS, Hill TM, Mikolajczyk SD, Millar LS, Kuus-Reichel K, Saedi MS. Expression of human glandular kallikrein, hK2, in mammalian cells. Cancer Res 1996;56:5397-402.
8. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS. Human glandular kallikrein (hK2) shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. Prostate 1998;34: 44-50.
9. Grauer L, Charlesworth MC, Saedi MS, Finlay JA, Liu R-S, Kuus-Reichel K, Tindall DJ. Identification of human glandular kallikrein hK2 from LNCaP cells. J Androl 1996;17:353-9.
10. Charlesworth MC, Young CYF, Klee GG, Saedi MS, Mikolajczyk SD, Finlay JA, Tindall DJ. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology 1997;49:487-93.
11. Darson M, Pacelli A, Roche P, Rittenhouse H, Wolfert R, Young CYF, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997;49:857-62.
12. Piironen T, Lovgren J, Karp M, Eerola R, Lundwall A, Dowell B. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem 1996;42 1034-41.
13. Deperthes D, Frenette G, Brillard-Bourdet M, Bourgois L, Gauthier F, Tremblay R, Dube JY. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J Androl 1996;17:659-65.
14. Lilja H, Christensson A, Dahlen U, Matikainen M-T, Nilsson O, Pettersson K, Lovgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
15. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
16. Mikolajczyk SD, Grauer L, Millar L, Hill T, Kumar A, Rittenhouse H, et al. A precursor form of PSA (proPSA) is a component of the free-PSA in prostate cancer serum. Urology 1997; 50:710-4.
17. Mikolajczyk SD, Millar LS, Marker KM, Grauer LS, Goel AS, Cass MMJ, et al. Alanine 217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein, hK2. Eur J Biochem 1997;246:440-6.
18. Kumar A, Mikolajczyk SD, Goel A, Millar L, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997;57:3111-4.
19. Ellis WJ, Vessella RL, Noteboom JL, Lange PH, Wolfert RL, Rittenhouse HG. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Urology 1997;50:573-9.
20. Saedi MS, Hill TM, Goel AS, Kumar A, Roche P. Assessment of the precursor form of human kallikrein (prohK2) as a marker for prostate cancer. J Urol 1997;157:442.
21. Grauer LS, Finlay JA, Mikolajczyk SD, Pusateri KD, Wolfert RL, Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. J Androl 1998;19:407-11.